Agilent Completes Acquisition of ACEA Biosciences
November 14 2018 - 5:30PM
Business Wire
Acquisition Brings Together Two Pioneers in
Cellular Function and Metabolism Measurements
Agilent Technologies Inc. (NYSE: A) today announced it has
completed the acquisition of ACEA Biosciences Inc. (ACEA), a
developer of cutting-edge cell analysis tools, for $250 million in
cash. This acquisition brings together two pioneers in cellular
function and metabolism measurements focused on real-time, live
cell analyses.
ACEA has developed two ground-breaking platforms that are
complementary to Agilent’s current portfolio. The ACEA xCELLigence®
RTCA technology is a unique impedance platform for label-free,
real-time cellular function measurements used in immuno-oncology,
pre-clinical drug discovery and development, as well as in basic
academic research. This technology is complemented by the
introduction in recent years of the NovoCyte® and NovoCyte
Quanteon™ portfolio of high performance bench top flow cytometry
systems.
ACEA also markets a clinical configuration of the NovoCyte
platform, currently commercialized in China. This provides a unique
opportunity in combination with Agilent’s Reagent Partnership
business within Agilent’s Diagnostics and Genomics Group which
provides reagents for flow cytometry.
“The Agilent and ACEA teams are united by a common goal to
provide the most innovative high-performance solutions for cell
analysis,” said Todd Christian, Vice President & General
Manager of Agilent’s Cell Analysis Division. “We are excited for
the opportunities we have as a newly combined team to provide the
most advanced tools for scientists performing cell analysis
workflows.”
ACEA is Agilent’s second acquisition this year in the cell
analysis space. In January, Agilent acquired Luxcel Biosciences, a
developer of real-time fluorescence plate-reader based in vitro
cell assay kits. Cell analysis is a key area of strategic focus for
Agilent.
ACEA was founded in 2002 and has its headquarters in San Diego
and a large manufacturing and R&D footprint in Hangzhou, China.
More than 2,500 ACEA instruments have been placed globally and have
been used in more than 1,800 peer-reviewed publications.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in life
sciences, diagnostics, and applied chemical markets. With more than
50 years of insight and innovation, Agilent instruments, software,
services, solutions, and people provide trusted answers to
customers' most challenging questions. The company generated
revenues of $4.47 billion in fiscal 2017 and employs 14,500 people
worldwide. Information about Agilent is available
at www.agilent.com. To receive the latest Agilent news,
subscribe to our Newsroom.
Follow on LinkedIn, Twitter, and Facebook.
Forward-Looking Statements
This news release contains forward-looking statements as defined
in the Securities Exchange Act of 1934 and is subject to the safe
harbors created therein. The forward-looking statements contained
herein include, but are not limited to, statements regarding the
opportunities the acquisition brings. These forward-looking
statements involve risks and uncertainties that could cause
Agilent’s results to differ materially from management’s current
expectations. Such risks and uncertainties include, but are not
limited to, the ability to integrate ACEA’s operations with
Agilent’s, retain key employees, meet customer expectations and
realize efficiencies from the combined businesses. In addition,
other risks that Agilent faces in running its operations include
the ability to execute successfully through business cycles; the
ability to meet and achieve the benefits of its cost-reduction
goals and otherwise successfully adapt its cost structures to
continuing changes in business conditions; ongoing competitive,
pricing and gross-margin pressures; the risk that our cost-cutting
initiatives will impair our ability to develop products and remain
competitive and to operate effectively; the impact of geopolitical
uncertainties and global economic conditions on our operations, our
markets and our ability to conduct business; the ability to improve
asset performance to adapt to changes in demand; the ability of our
supply chain to adapt to changes in demand; the ability to
successfully introduce new products at the right time, price and
mix; the ability of Agilent to successfully integrate recent
acquisitions; the ability of Agilent to successfully comply with
certain complex regulations; and other risks detailed in Agilent’s
filings with the Securities and Exchange Commission, including our
quarterly report on Form 10-Q for the quarter ended July 31, 2018.
Forward-looking statements are based on the beliefs and assumptions
of Agilent’s management and on currently available information.
Agilent undertakes no responsibility to publicly update or revise
any forward-looking statement.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available at www.agilent.com/go/news.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181114005957/en/
EDITORIAL CONTACTS:
Agilent Technologies:Victoria Wadsworth-Hansen (Business)+1 408
553 2005+ 45 29336980victoria.wadsworth-hansen@agilent.com
Stefanie Notaney (Enterprise)+1 408 345
8955stefanie.notaney@agilent.com
INVESTOR CONTACT:
Alicia Rodriguez+1 408 345 8948alicia_rodriguez@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024